<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014061</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number: 2021-001466-37</org_study_id>
    <nct_id>NCT05014061</nct_id>
  </id_info>
  <brief_title>Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction</brief_title>
  <acronym>A-STAMI</acronym>
  <official_title>Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction An Open-label, Single Center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of adenosine on the recovery of myocardial&#xD;
      akinesia in ST-elevation myocardial infarction (STEMI). The study is a single-center&#xD;
      randomized clinical trial intending to include 90 patients.&#xD;
&#xD;
      The objective of the study is to investigate whether treatment with adenosine hastens&#xD;
      recovery of myocardial akinesia and improves cardiac function at 48 hours in patients with&#xD;
      STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint (variable):&#xD;
&#xD;
      The resolution of myocardial stunning at 48 hours (StunningRes48h).&#xD;
&#xD;
      The proportion of stunning that has resolved at 48 hours will be calculated according to the&#xD;
      formula:&#xD;
&#xD;
      StunningRes48h = (%AkinesiaBaseline - %Akinesia48h) / (%AkinesiaBaseline - %Akinesia30days)&#xD;
      where %AkinesiaT is defined as the endocardial length of the akinetic myocardium measured in&#xD;
      end-diastole divided by the total endocardial length measured in end-diastole in the 2- and&#xD;
      4-chamber view, at time T (T= 48h or 30 days)&#xD;
&#xD;
      Secondary endpoint(s) (variables):&#xD;
&#xD;
        1. Infarct size at 6 months, as assessed by cardiac magnetic resonance imaging (magnetic&#xD;
           resonance imaging).&#xD;
&#xD;
        2. Ejection fraction days 1, 2, 3, 7, 14, 30 and 6 months.&#xD;
&#xD;
        3. Any sustained ventricular tachycardia or fibrillation within 72 hours (safety endpoint;&#xD;
           binary)&#xD;
&#xD;
        4. Any high-grade atrioventricular block or sinus arrest within 72 hours (safety endpoint;&#xD;
           binary)&#xD;
&#xD;
        5. Implantation of cardiac assist device within 72 hours (binary)&#xD;
&#xD;
        6. Stroke within 6 months (binary)&#xD;
&#xD;
        7. All-cause mortality within 6 months&#xD;
&#xD;
        8. Heart failure rehospitalization within 6 months*&#xD;
&#xD;
        9. Worsening in-hospital heart failure ≥12 hours after PCI#&#xD;
&#xD;
       10. Composite of any worsening in-hospital heart failure ≥12 hours after PCI or heart&#xD;
           failure rehospitalization within 6 months.&#xD;
&#xD;
             -  Defined as re-admission to hospital after discharge, with a total length of&#xD;
                admission ≥24 hours, documented worsening of heart failure signs or symptoms (e.g.&#xD;
                worsening dyspnea, fatigue, edema/fluid overload, pulmonary venous distension or&#xD;
                signs of pulmonary edema on X-ray), with administration of intravenous diuretic or&#xD;
                inotropic drugs, ultrafiltration, non-invasive ventilation or mechanical assist&#xD;
                device.&#xD;
&#xD;
                  -  Defined as intensification of heart failure therapy due to worsening heart&#xD;
                     failure signs or symptoms (as above; including intravenous diuretic, inotropic&#xD;
                     or vasopressor drugs, non-invasive ventilation or mechanical assist device).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, open-label, randomized controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The resolution of myocardial stunning at 48 hours (StunningRes48h).</measure>
    <time_frame>48 hours</time_frame>
    <description>The proportion of stunning that has resolved at 48 hours will be calculated according to the formula:&#xD;
StunningRes48h = (%AkinesiaBaseline - %Akinesia48h) / (%AkinesiaBaseline - %Akinesia30days) where %AkinesiaT is defined as the endocardial length of the akinetic myocardium measured in end-diastole divided by the total endocardial length measured in end-diastole in the 2- and 4-chamber view, at time T (T= 48h or 30 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size</measure>
    <time_frame>6 months</time_frame>
    <description>Infarct size, assessed by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 7, Day 14, Day 30 and 6 months</time_frame>
    <description>Ejection fraction, assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained ventricular tachycardia or fibrillation</measure>
    <time_frame>72 hours</time_frame>
    <description>Any sustained ventricular tachycardia or fibrillation within 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-grade atrioventricular block or sinus arrest</measure>
    <time_frame>72 hours</time_frame>
    <description>Any high-grade atrioventricular block or sinus arrest within 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac assist device</measure>
    <time_frame>72 hours</time_frame>
    <description>Implantation of cardiac assist device within 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months</time_frame>
    <description>Stroke within 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>All-cause mortality within 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Heart failure rehospitalization within 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening heart failure</measure>
    <time_frame>≥12 hours</time_frame>
    <description>Worsening in-hospital heart failure after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite</measure>
    <time_frame>≥12 hours or 6 months</time_frame>
    <description>Composite of any worsening in-hospital heart failure ≥12 hours after PCI or heart failure rehospitalization within 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Adenosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controll</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine infusion 70 µg/kg/min for 6 hours</description>
    <arm_group_label>Adenosine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years.&#xD;
&#xD;
          2. Anterior STEMI.&#xD;
&#xD;
          3. Symptom duration ≤6 hours&#xD;
&#xD;
          4. Written informed consent obtained - Angiographic Inclusion criteria:&#xD;
&#xD;
               1. Culprit lesion in LAD, major branch of LAD, proximal or mid LCx or proximal or&#xD;
                  mid RCA&#xD;
&#xD;
               2. TIMI flow ≤2 in the culprit vessel&#xD;
&#xD;
                  -Echocardiographic inclusion criteria:&#xD;
&#xD;
               3. Detectable hypo- or akinesia corresponding to ≥5% of the left ventricle&#xD;
                  corresponding to culprit lesion, per bedside visual assessment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous randomization in the study&#xD;
&#xD;
          2. Any of the following contraindications for treatment with adenosine:&#xD;
&#xD;
               1. Known pre-existing atrioventricular block grade ≥2 or sick sinus syndrome in&#xD;
                  patients without pacemaker.&#xD;
&#xD;
               2. Known pre-existing elevation of intracranial pressure&#xD;
&#xD;
               3. Treatment with dipyridamole within 24 hours of randomization&#xD;
&#xD;
               4. Systolic blood pressure &lt;80 mm Hg at screening&#xD;
&#xD;
          3. Any concomitant condition resulting in a life expectancy of less than one month&#xD;
&#xD;
          4. Previous myocardial infarction or other cardiac condition resulting in impaired&#xD;
             regional or global systolic function without documented recovery of cardiac function&#xD;
&#xD;
          5. Heart transplant or left ventricular assist device recipient&#xD;
&#xD;
          6. Not suitable in the opinion of the investigator due to severe or terminal comorbidity&#xD;
             with poor prognosis or characteristics that may interfere with adherence to the trial&#xD;
             protocol&#xD;
&#xD;
          7. Pregnancy or woman of childbearing potential who is not sterilized or using a&#xD;
             medically accepted form of contraception -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Redfors, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vastra Gotaland Region</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandeep Jha, MD</last_name>
    <phone>+46 738491912</phone>
    <email>sandeep.jha@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margareta Scharin Täng, PhD</last_name>
    <phone>+46 700207968</phone>
    <email>margareta.scharin.tang@vgregion.se</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

